Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.63 USD | +1.24% | -2.98% | +5.16% |
Business Summary
Number of employees: 121
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Probody Therapeutics
100.0
%
| 53 | 100.0 % | 101 | 100.0 % | +90.38% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 53 | 100.0 % | 101 | 100.0 % | +90.38% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Chris Ogden
DFI | Director of Finance/CFO | 40 | 21-08-01 |
Marcia Belvin
CTO | Chief Tech/Sci/R&D Officer | 57 | 17-12-31 |
Yu Waye Chu
CTO | Chief Tech/Sci/R&D Officer | 56 | 23-07-16 |
Lloyd Rowland
CMP | Compliance Officer | 67 | 18-04-30 |
Jeffrey Landau
PRN | Corporate Officer/Principal | 46 | 21-03-31 |
Hong He
PRN | Corporate Officer/Principal | 55 | 20-01-31 |
Danielle Olander
HRO | Human Resources Officer | - | 14-07-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
James Meyers
BRD | Director/Board Member | 58 | 18-12-19 |
Elaine Jones
BRD | Director/Board Member | 69 | 14-11-30 |
Sean McCarthy
CEO | Chief Executive Officer | 57 | 10-11-30 |
Mani Mohindru
BRD | Director/Board Member | 52 | 20-12-15 |
Halley Gilbert
BRD | Director/Board Member | 54 | 20-04-26 |
Matthew Young
BRD | Director/Board Member | 54 | 15-10-31 |
Alan Ashworth
BRD | Director/Board Member | 63 | 21-09-28 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 67,731,764 | 66,926,077 ( 98.81 %) | 0 | 98.81 % |
Company contact information
CytomX Therapeutics, Inc.
151 Oyster Point Boulevard Suite 400
94080-1913, South San Francisco
+650 515 3185
http://www.cytomx.comSector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.16% | 110M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.33% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- CTMX Stock
- Company CytomX Therapeutics, Inc.